The government should focus on keeping up the funding for HIV to continue to innovate in this space, potentially eliminating the virus altogether.
Patrick Sullivan, DVM, PhD
Advertisement
Infectious disease epidemiologist and a professor of epidemiology at Emory University's Rollins School of Public Health in Atlanta
Articles by Patrick Sullivan, DVM, PhD
Funding cuts for research intended to make treatment and cures available and accessible for patients with HIV could affect HIV care in the long term.
Several actions taken by the current administration may affect the landscape of prevention of HIV, prompting an analysis of these effects.
Any potential reduction in access to pre-exposure prophylaxis (PrEP) would increase both cost and the number of diagnoses of HIV.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
3
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
4
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
5